Multiple protonation states of vesicular acetylcholine transporter detected by binding of [3H]vesamicol.
Vesicular acetylcholine transporter (VAChT) is inhibited by (-)-vesamicol [(-)-trans-2-(4-phenylpiperidino)cyclohexanol], which binds tightly to an allosteric site. The tertiary alkylamine center in (-)-vesamicol is protonated and positively charged at acidic and neutral pH and unprotonated and uncharged at alkaline pH. Deprotonation of the amine has been taken to explain loss of (-)-vesamicol binding at alkaline pH. However, binding data deviate from a stereotypical bell shape, and more binding occurs than expected at alkaline pH. The current study characterizes the binding of (-)-vesamicol from pH 5 to pH 10 using filter assays, (-)-[3H]vesamicol (hereafter called [3H]vesamicol), and human VAChT expressed in PC12(A123.7) cells. At acidic pH, protons and [3H]vesamicol compete for binding to VAChT. Preexposure or long-term exposure of VAChT to high pH does not affect binding, thus eliminating potential denaturation of VAChT and failure of the filter assay. The dissociation constant for the complex between protonated [3H]vesamicol and VAChT decreases from 12 nM at neutral pH to 2.1 nM at pH 10. The simplest model of VAChT that explains the behavior requires a proton at site 1 to dissociate with pK1 = 6.5 +/- 0.1, a proton at site A to dissociate with pKA = 7.6 +/- 0.2, and a proton at site B to dissociate with pKB = 10.0 +/- 0.1. Deprotonation of the site 1 proton is obligatory for [3H]vesamicol binding. Deprotonation of site A decreases affinity (2.2 +/- 0.5)-fold, and deprotonation of site B increases affinity (18 +/- 4)-fold. Time-dependent dissociation of bound [3H]vesamicol is biphasic, but equilibrium saturation curves are not. The contrasting phasicity suggests that the pathway to and from the [3H]vesamicol binding site exists in open and at least partially closed states. The potential significance of the findings to development of PET and SPECT ligands based on (-)-vesamicol for human diagnostics also is discussed.
Khare
Parul
P
Department of Chemistry and Biochemistry, Neuroscience Research Institute, University of California, Santa Barbara, California 93106, USA.
White
Aubrey R
AR
Parsons
Stanley M
SM
D000495:Allosteric Site; D000818:Animals; D001667:Binding, Competitive; D004795:Enzyme Stability; D006801:Humans; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D007700:Kinetics; D008956:Models, Chemical; D016716:PC12 Cells; D010880:Piperidines / Q000378:metabolism* / Q000494:pharmacology; D011522:Protons; D051381:Rats; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D014316:Tritium; D050494:Vesicular Acetylcholine Transport Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*
D010880:Piperidines; D011522:Protons; D011994:Recombinant Proteins; C493459:SLC18A3 protein, human; D050494:Vesicular Acetylcholine Transport Proteins; D014316:Tritium; C006189:vesamicol
J Neurochem. 1998 Sep;71(3):1118-26
9721736
Neurology. 2005 Jan 25;64(2):208-15
15668415
J Med Chem. 2009 Mar 12;52(5):1358-69
19203271
Biochemistry. 2005 Jun 7;44(22):7955-66
15924414
J Neurochem. 1986 Apr;46(4):1214-8
3950625
J Biol Chem. 1997 Feb 28;272(9):5403-8
9038139
J Cell Biol. 1994 Dec;127(6 Pt 1):1603-16
7798315
Eur J Nucl Med Mol Imaging. 2002 Mar;29(3):416-34
12002720
Neuroreport. 1993 Sep 30;4(12):1311-4
8260611
Eur J Pharmacol. 1996 May 23;304(1-3):185-90
8813601
Protein Sci. 2004 Jul;13(7):1832-40
15215526
Biochemistry. 1988 Jul 12;27(14):5262-7
2844255
Science. 2006 May 5;312(5774):741-4
16675700
Protein Eng. 1994 Mar;7(3):291-9
8177877
Science. 2003 Aug 1;301(5633):616-20
12893936
Neurochem Int. 2000 Feb;36(2):113-7
10676874
Biochemistry. 1998 Sep 22;37(38):13400-10
9748347
Anal Biochem. 1976 May 7;72:248-54
942051
J Biol Chem. 2000 Mar 3;275(9):6175-80
10692409
Exp Neurol. 2003 Nov;184 Suppl 1:S68-79
14597329
FASEB J. 2000 Dec;14(15):2423-34
11099460
Science. 2003 Aug 1;301(5633):610-5
12893935
Methods Enzymol. 2004;385:169-84
15130739
Biochemistry. 2004 Sep 7;43(35):11163-74
15366926
Biochimie. 1982 Oct;64(10):915-21
6817822
Int Rev Neurobiol. 1993;35:279-390
8463062
Annu Rev Microbiol. 2008;62:289-305
18537473
J Biol Chem. 1999 Jan 8;274(2):673-80
9873001
J Biol Chem. 2001 Nov 9;276(45):41580-7
11551909
Mol Membr Biol. 2008 Sep;25(6-7):571-83
19037818
Biochemistry. 1992 Jun 30;31(25):5752-62
1319200
Trends Neurosci. 1995 May;18(5):218-24
7610492
Mol Pharmacol. 1993 Sep;44(3):633-41
8371715
Methods Mol Biol. 2010;637:181-219
20419436
Anal Bioanal Chem. 2004 Mar;378(6):1428-48
15214406
Neurochem Res. 2000 Oct;25(9-10):1385-96
11059809
Nat Struct Biol. 2002 Aug;9(8):597-600
12118242
J Biol Chem. 1996 Nov 1;271(44):27229-32
8910293
Mol Pharmacol. 1983 Mar;23(2):431-6
6835201
Biochem Pharmacol. 1995 Mar 15;49(6):791-7
7702637
J Mol Microbiol Biotechnol. 1999 Nov;1(2):257-79
10943556
J Med Chem. 1989 Jun;32(6):1217-30
2724295
J Nucl Med. 1996 Jul;37(7):1192-7
8965197
Biol Psychiatry. 2001 Feb 1;49(3):211-20
11230872